Watch RKDA. Know when insiders buy.
One email the day a filing lands. Free.
RKDA
Arcadia Biosciences, Inc.
0.16
+0.00 +2.94%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $379KP/E —DIV YIELD —FCF YIELD —REV TTM $4.7M −12.2%NET INCOME −$11.1MNET CASH $4.1M52W 0.14 – 4.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.4M | −0.8% | 43.7% | −$496K | −$6.3M | — | -2.09 | −$319K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $1.1M | −8.3% | 36.4% | −$779K | −$4.4M | −268.7% | -2.11 | −$1.1M | — | — | May 14 |
| Q4 2025 · Dec 31derived | $901K | −25.9% | 21.3% | −$1.4M | −$1.3M | — | -0.98 | −$822K | $0 | −$822K | Aug 13 |
| Q3 2025 · Sep 30 | $1.3M | −15.3% | 32.1% | −$1.2M | $856K | — | 0.62 | −$257K | $0 | −$257K | Nov 7 |
| Q2 2025 · Jun 30 | $1.5M | +11.4% | 43.4% | −$501K | −$4.5M | −520.2% | -3.26 | −$2M | $0 | −$2M | Aug 13 |
| Q1 2025 · Mar 31 | $1.2M | +21.6% | 43.2% | $530K | $2.6M | — | 1.90 | −$1.6M | $0 | −$1.6M | May 14 |
| Q4 2024 · Dec 31derived | $1.2M | +56.5% | 32.0% | −$2.3M | −$4.1M | — | -2.99 | −$2.2M | $0 | −$2.2M | Mar 26 |
| Q3 2024 · Sep 30 | $1.5M | +18.4% | 32.9% | −$1.8M | −$1.6M | — | -1.18 | −$1.8M | $0 | −$1.8M | Nov 7 |
| Q2 2024 · Jun 30 | $1.3M | — | 51.5% | $2M | $1.1M | — | 0.78 | −$2.5M | $3K | −$2.5M | Aug 14 |
| Q1 2024 · Mar 31 | $987K | — | 52.3% | −$1.6M | −$2.4M | — | -1.78 | −$3.2M | $13K | −$3.2M | May 8 |
| Q4 2023 · Dec 31derived | $777K | — | 77.1% | −$1.2M | −$2.9M | — | -1.98 | −$4.1M | $0 | −$4.1M | Mar 25 |
| Q3 2023 · Sep 30 | $1.3M | — | 37.0% | −$1.4M | −$2.6M | — | -1.89 | −$2.9M | $0 | −$2.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $4.9M | 36.2% | −$2.5M | −$2.3M | -48.1% | -1.71 | −$4.7M | $0 | −$4.7M | — | — |
| FY2024 · to Dec 31 | $5M | 41.3% | −$3.6M | −$7M | -139.5% | -5.17 | −$9.6M | $16K | −$9.6M | — | — |
| FY2023 · to Dec 31 | $4.5M | 51.2% | −$6.1M | −$14M | -313.9% | -11.29 | −$15.3M | $5K | −$15.3M | — | — |
| FY2022 · to Dec 31 | $7.4M | 17.8% | −$14M | −$15.4M | -207.3% | -25.65 | −$14M | $72K | −$14M | — | — |
| FY2021 · to Dec 31 | $6.8M | -28.4% | −$35.5M | −$14.7M | -216.2% | -27.56 | −$25.9M | $1M | −$26.9M | — | — |
| FY2020 · to Dec 31 | $8M | 35.3% | −$12.8M | −$4.7M | -57.9% | -0.47 | −$30.2M | $2.3M | −$32.6M | — | — |
Every number comes from Arcadia Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.